People with type 1 diabetes in Europe will have access to a new continuous glucose monitor (CGM), which received the CE mark this week.
The CGM, which joins systems from Medtronic and Abbott already on the European market, and available in the UK, had previously only been available in the US.
Maker Dexcom Inc. announced yesterday the European approval for the ‘Seven,’ its seven-day continuous glucose monitoring system, enabling commercialisation of the system in the European Union and some countries in Asia and Latin America
JDRF research, released this year at the European Association for the Study of Diabetes (EASD) annual meeting in Rome, demonstrated that continuous glucose monitoring can significantly improve control.
Initial results of a randomised controlled clinical trial across ten sites in the USA demonstrated that participants experienced an improvement in their HbA1C levels.
Further research has shown that a 10% reduction in HbA1Cs can result in a 40% reduction in the risk of complications.
JDRF Chief Executive Karen Addington said: “Our research has shown that CGMs, worn over a long period of time, significantly improve blood glucose control in people with type 1 diabetes. We welcome all developments which increase choice for people with type 1 diabetes and may improve access to this important technology.”
Those who are interested in using a CGM should consult their diabetes team.
Read more about the CGM trial funded by JDRF.